Today: 2 July 2026
Browse Category

NASDAQ:TERN 16 December 2025 - 12 May 2026

Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals shares aren’t budging—not surprising, since the merger is done and Nasdaq trading is finished. The last quote for the stock came in at $52.95, just shy of Merck’s $53-per-share cash deal. With Terns now fully absorbed into Merck, its common stock has dropped off the Nasdaq Global Select Market and won’t trade again. This explains the chart’s flatline—no real movement left. When a cash buyout is nearly a done deal, the shares just shadow the expected payout, with barely any margin for risk or timing. In this case, almost no spread remained after Merck wrapped up its tender offer, leaving leftover shares automatically converted to $53 cash per share.
12 May 2026
····
Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

In U.S. premarket action Thursday, Terns Pharmaceuticals was pegged at $52.86, matching Wednesday’s close and sitting roughly 14 cents under Merck’s $6.7 billion all-cash bid for the biotech. Terns had surged 5.8% by the end of Wednesday’s session. The slim spread signals that investors are betting the deal will likely go through as planned. This is not just about Terns—Merck is under pressure to diversify, aiming to soften its reliance on Keytruda ahead of the drug’s looming U.S. exclusivity loss in 2028.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion cash deal, offering $53 per share, the companies said Wednesday. The move hands Merck an experimental leukemia drug and underlines its push into oncology. The announcement followed a Financial Times report earlier in the day that discussions were already advanced. Timing is crucial here. Merck’s blockbuster cancer drug Keytruda faces some patent expirations in 2028. In 2025, Keytruda pulled in over $30 billion—almost half of Merck’s total revenue—so investors are watching closely for signs of what comes next. The company is racing to lock down fresh sources of growth.
25 March 2026
··
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

December 18, 2025 — Terns Pharmaceuticals, Inc. is pulling back in Thursday trading after one of the most explosive biotech runs of the year, with investors digesting a fresh wave of clinical-trial enthusiasm, a major equity raise, and a fast-updating stack of Wall Street price targets. As of the latest available trading update on Dec. 18, 2025, TERN stock was around $39.62, after opening near $42.55 and trading in a $39.62–$42.59 intraday range, with volume above 2.0 million shares.
18 December 2025
··

Stock Market Today

  • Haleon CFO Dawn Allen Gets Share Award, Sells Part to Pay Tax
    July 2, 2026, 10:30 AM EDT. Haleon PLC (LSE/NYSE: HLN) said CFO Dawn Allen was given a Performance Share Plan award that vests June 30, 2026. She got 283,193 shares under the 2024 plan, based on targets through December 2025. Allen sold 133,301 shares at £3.52 each in London to cover taxes owed from the vesting. Shares include dividends and are subject to malus and clawback. The company made the disclosure under UK rules and reminded that execs have to hold shares for two years after they vest. Details will be in next year's annual report and 20-F.
Go toTop